Overview
- Faruqi & Faruqi, which issued a Wednesday reminder, cites June 8, 2026 as the deadline for investors to seek lead-plaintiff status in the filed case.
- Other notices from firms including The Schall Law Firm and DJS Law Group list a June 5, 2026 cutoff, creating a split that investors are being told to confirm with the court.
- The complaint alleges Medpace told investors its project cancellations were “well behaved” while concealing higher-than-reported cancellations that undercut growth expectations.
- Medpace disclosed on February 9, 2026 that its fourth-quarter 2025 book-to-bill ratio was 1.04 versus guidance of 1.15, and the stock fell 15.9% to $446.05 the next trading day.
- The proposed class covers purchases from April 22, 2025 through February 9, 2026, and no class has been certified as firms recruit investors on a contingency-fee basis.